Bank of America’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-2,700
| Closed | -$84.5K | – | 7677 |
|
|
2023
Q4 | $84.5K | Hold |
2,700
| – | – | ﹤0.01% | 6439 |
|
|
2023
Q3 | $56.3K | Buy |
+2,700
| New | +$73.3K | ﹤0.01% | 6465 |
|
|
2023
Q1 | – | Sell |
-30,000
| Closed | -$478K | – | 7751 |
|
|
2022
Q4 | $478K | Buy |
+30,000
| New | +$469K | ﹤0.01% | 5414 |
|
|
2021
Q1 | – | Sell |
-15,200
| Closed | -$813K | – | 7380 |
|
|
2020
Q4 | $813K | Buy |
+15,200
| New | +$755K | ﹤0.01% | 4669 |
|
|
2019
Q4 | – | Sell |
-162,200
| Closed | -$5.84M | – | 7033 |
|
|
2019
Q3 | $5.84M | Buy |
+162,200
| New | +$4.92M | ﹤0.01% | 3047 |
|
|
2019
Q2 | – | Sell |
-10,800
| Closed | -$290K | – | 7139 |
|
|
2019
Q1 | $290K | Buy |
+10,800
| New | +$252K | ﹤0.01% | 5331 |
|
|
2018
Q3 | – | Sell |
-19,800
| Closed | -$302K | – | 7231 |
|
|
2018
Q2 | $302K | Sell |
19,800
-173,800
| -90% | -$3.1M | ﹤0.01% | 5185 |
|
|
2018
Q1 | $4.35M | Buy |
+193,600
| New | +$5.36M | ﹤0.01% | 3215 |
|
|
2017
Q2 | – | Sell |
-14,900
| Closed | -$512K | – | 6906 |
|
|
2017
Q1 | $512K | Buy |
+14,900
| New | +$526K | ﹤0.01% | 4875 |
|
|
2016
Q3 | – | Sell |
-20,000
| Closed | -$649K | – | 7069 |
|
|
2016
Q2 | $649K | Buy |
20,000
+19,500
| +3,900% | +$653K | ﹤0.01% | 4485 |
|
|
2016
Q1 | $14K | Sell |
500
-1,200
| -71% | -$26.2K | ﹤0.01% | 6266 |
|
|
2015
Q4 | $61K | Buy |
1,700
+500
| +42% | +$17.6K | ﹤0.01% | 5959 |
|
|
2015
Q3 | $40K | Hold |
1,200
| – | – | ﹤0.01% | 6032 |
|
|
2015
Q2 | $50K | Sell |
1,200
-345,900
| -100% | -$13.4M | ﹤0.01% | 5937 |
|
|
2015
Q1 | $11.3M | Buy |
347,100
+328,800
| +1,797% | +$11.3M | ﹤0.01% | 1758 |
|
|
2014
Q4 | $581K | Sell |
18,300
-6,400
| -26% | -$181K | ﹤0.01% | 4509 |
|
|
2014
Q3 | $612K | Sell |
24,700
-3,400
| -12% | -$79.5K | ﹤0.01% | 4397 |
|
|
2014
Q2 | $635K | Sell |
28,100
-8,700
| -24% | -$182K | ﹤0.01% | 4399 |
|
|
2014
Q1 | $895K | Sell |
36,800
-113,800
| -76% | -$2.88M | ﹤0.01% | 4017 |
|
|
2013
Q4 | $3.76M | Buy |
150,600
+68,800
| +84% | +$1.62M | ﹤0.01% | 2728 |
|
|
2013
Q3 | $2.25M | Buy |
81,800
+53,200
| +186% | +$1.11M | ﹤0.01% | 3157 |
|
|
2013
Q2 | $519K | Buy |
+28,600
| New | +$394K | ﹤0.01% | 4707 |
|
Other funds holding ACAD
BBA
VPM
RI
VCM
PAI
Bank of America's ACAD Position: Q1 2026 in Review
Bank of America increased its Acadia Pharmaceuticals (ACAD) stake by 27% in Q1 2026, buying an estimated $7.94M and bringing the position to 1,553,770 shares worth $34.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1913.
Bank of America first reported a position in ACAD in Q2 2013 and has held it in 52 quarters since. 342 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.
- Bank of America held 1,553,770 shares of Acadia Pharmaceuticals worth $34.6M as of Q1 2026.
- Bank of America bought 332,325 Acadia Pharmaceuticals shares in Q1 2026, an estimated $7.94M.
- Acadia Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1913 holding.
- Bank of America first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- 342 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.